Genta announces EMA Orphan Drug designation for tesetaxel

Genta Incorporated (OTCBB: GETA.OB) today announced that tesetaxel, the leading oral taxane in clinical development, has been designated as an Orphan Drug by the European Medicines Agency for gastric cancer. The drug has previously received Orphan Drug designation by the U.S. Food and Drug Administration for both gastric cancer and melanoma, as well as Fast Track designation by FDA for gastric cancer.

Orphan designation for a medicinal product by the EMA provides for scientific advice during the product-development phase, direct access to centralized marketing authorization, and certain financial incentives. The designation also provides 10 years of marketing exclusivity subsequent to approval. Orphan drugs are eligible for full (100%) reduction of fees associated with pre-authorization inspections, as well as full reduction of marketing application fees and annual fees for qualifying companies. Earlier this year, Genta's qualifying status for this purpose as a "small and medium-sized enterprise" was renewed by the EMA.


Genta Incorporated


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA approval of lifileucel: A milestone in tumor-infiltrating lymphocyte therapy for advanced melanoma